Skip to content

Net Income at other companies

Pfizer logo
PfizerPFE
$2.7B-9.3%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Incyte logo
IncyteINCY
$303.33M+91.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$45.51M-14.1%
CG Oncology logo
CG OncologyCGON
-$60.2M-74.7%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$73.29M+4.9%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s net income?
Cogent Biosciences, Inc. (COGT) reported net income of -$97.35M in Q1 2026.
How has Cogent Biosciences, Inc.'s net income changed year-over-year?
Cogent Biosciences, Inc.'s net income decreased by 35.2% year-over-year, from -$71.99M to -$97.35M.
What is the long-term trend for Cogent Biosciences, Inc.'s net income?
Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s net income has grown at a 46.1% compound annual growth rate (CAGR), from -$72.27M to -$328.94M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.